Day 1 - Thursday, September 25, 2008

	5:00 - 5:15 PM	Welcome and Overview of Program Kenneth E. Sherman, MD, PhD University of Cincinnati College of Medicine
	5:15 - 5:35 PM	Epidemiology of HIV in 2008 John T. Brooks, MD Centers for Disease Control and Prevention
	5:35 - 6:00 PM	HIV Treatment Guidelines, 2008 Judith Feinberg, MD University of Cincinnati College of Medicine
	6:00 - 6:25 PM	Epidemiology of Liver Disease in HIV Richard K. Sterling, MD, MSc Virginia Commonwealth University
	6:25 - 6:40 PM	SELECTED ORAL PRESENTATION Decreasing Liver-Related Mortality Associated With a Decreasing Prevalence of HCV Coinfection: Data From the HIV Atlanta VA Cohort Study (HAVACS) David Rimland, MD Atlanta VA Medical Center
	6:40 - 6:55 PM	SELECTED ORAL PRESENTATION A 4-Year Follow-Up of a Cohort of HIV-Positive Cirrhotic Patients Paula Tuma, MD University Complutense Hospital Carlos III
	7:00 - 8:30 PM	Poster Session and Welcome Reception

Day 2 - Friday, September 26, 2008

	7:30 - 8:05 AM	Liver Pathology in HIV Zachary D. Goodman, MD, PhD Armed Forces Institute of Pathology
	8:05 - 8:20 AM	SELECTED ORAL PRESENTATION Comparison of FIB-4 and APRI in HIV-HCV Coinfected Patients With Normal and Elevated ALT Amy Shah , MD Virginia Commonwealth University
	8:20 - 8:35 AM	SELECTED ORAL PRESENTATION Liver Fibrosis in Patients With Chronic Hepatitis C and Persistently Normal Transaminases - Influence of HIV Infection in the HAART Era Vincent Soriano, MD, PhD University Complutense Hospital Carlos III
	8:35 - 8:50 AM	SELECTED ORAL PRESENTATION Risk Factors for Advanced Liver Fibrosis in HIV-Infected Individuals: Role of Metabolic Abnormalities Pablo Barreiro, MD, PhD University Complutense Hospital Carlos II
	8:50 - 9:10 AM	Panel Discussion: Role of Noninvasive Markers of Liver Injury in 2008 Zachary D. Goodman, MD, PhD Vincent Soriano, MD, PhD Pablo Barreiro, MD, PhD
	9:10 - 9:30 AM	Break
	9:30 - 10:00 AM	Immunopathogenesis of Liver Injury in HIV Margaret J. Koziel, MD Beth Israel Deaconess Medical Center
	10:00 - 10:20 AM	New Forms of Liver Injury in HIV Infected Patients Richard M. Green, MD Northwestern University-Feinberg School of Medicine
	10:20 - 10:45 AM	Steatosis/Insulin Resistance in HIV Marshall J. Glesby, MD, PhD Weill Cornell Medical College
	10:45 - 11:00 AM	SELECTED ORAL PRESENTATION Unexplained Severe Portal Hypertension in HIV Patients: A New Clinical Entity? Vincent Soriano, MD, PhD University Complutense Hospital Carlos III
	11:00 - 11:25 AM	Role of Alcohol in Mediation of Hepatic Injury in HIV-Infected Patients Craig J. McClain, MD University of Louisville
	11:25 - 11:50 AM	Panel Discussion: Liver Injury Margaret J. Koziel, MD Richard M. Green, MD Marshall J. Glesby, MD, PhD Craig J. McClain, MD
	11:50 AM - 1:00 PM	Clinical Case Lunch Breakout: Meet the Professor
	1:00 - 1:20 PM	HIV and HCV Virology Jason T. Blackard, PhD University of Cincinnati College of Medicine
	1:20 - 1:45 PM	HCV and HBV Mutation and Evolution Stuart Ray, MD Johns Hopkins University School of Medicine
	1:45 - 2:10 PM	Effect of Host Genetic Polymorphisms Matthew J. Dolan, MD, FACP San Antonio Military Medical Center
	2:10 - 2:35 PM	Mechanisms of ART Liver Injury Timothy J. Davern II, MD University of California at San Francisco
	2:35 - 2:50 PM	SELECTED ORAL PRESENTATION Apoptosis in HCV and HCV/HIV Coinfected Patients: Evaluation Using M30 Serum Caspase Assay Philippe J. Zamor, MD University of Cincinnati College of Medicine
	2:50 - 3:10 PM	Break
	3:10 - 3:40 PM	HCV Targets and Therapeutic Agents Raymond T. Chung, MD Harvard Medical School
	3:40 - 4:10 PM	FDA Drug Development Issues in Patients With Liver Disease Russell D. Fleischer, PA-C, MPH US Food and Drug Administration
	4:10 - 4:25 PM	SELECTED ORAL PRESENTATION HCV Relapse After Peg-Interferon (IFN) Plus Ribavirin (RBV) Therapy: Is 12-Week Assessment Upon Completion of Treatment Enough to Determine Sustained HCV Clearance? Pablo Barreiro, MD, PhD University Complutense Hospital Carlos III
	4:25 - 4:40 PM	SELECTED ORAL PRESENTATION HCV Treatment Eligibility in ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Adeel A. Butt, MD, MS University of Pittsburgh School of Medicine
	4:40 - 4:50 PM	Closing Remarks Kenneth E. Sherman, MD, PhD

Day 3 - Saturday, September 27, 2008

	7:00 - 7:30 AM	Continental Breakfast
	7:30 - 7:55 AM	HBV/HIV Epidemiology and Natural History Vincent Soriano, MD, PhD University Complutense Hospital Carlos III
	7:55 - 8:25 AM	HBV Treatment in HIV Barbara H. McGovern, MD Tufts University
	8:25 - 8:40 AM	SELECTED ORAL PRESENTATION Cytokine Expression During Chronic Versus Occult Hepatitis B Virus Infection in HIV Coinfected Individuals Christina M. Martin, BS University of Cincinnati College of Medicine
	8:40 - 8:55 AM	SELECTED ORAL PRESENTATION Outcome of Chronic Hepatitis Delta in Patients With and Without HIV Infection in the HAART Era Paula Tuma, MD University Complutense Hospital Carlos III
	8:55 - 9:25 AM	Research Questions in HCV and HBV Management: Panel Discussion Barbara H. McGovern, MD Raymond T. Chung, MD Vincent Soriano MD, PhD
	9:25 - 9:45 AM	Break
	9:45 - 10:05 AM	Progression of Decompensated Liver Disease in Patients With HIV Margaret V. Ragni, MD, MPH University of Pittsburgh Medical School
	10:05 - 10:25 AM	Selection and Outcome of Liver Transplant Candidates With HIV Peter G. Stock, MD, PhD University of California at San Francisco
	10:25 - 10:40 AM	SELECTED ORAL PRESENTATION HCV Infection and Cirrhosis Are Key Risk Factors for Thrombocytopenia in the Era of Potent Antiretroviral Therapy Kristen M. Marks, MD Weill Cornell Medical College
	10:40 - 11:00 AM	Panel Discussion: End-Stage Liver Disease Margaret V. Ragni, MD, MPH Peter G. Stock, MD, PhD
	11:00 - 11:10 AM	Break
	11:10 - 11:30 AM	Management Issues in HIV-infected Patients With Unhealthy Alcohol Use Jeffrey H. Samet, MD, MA, MPH Boston University Schools of Medicine and Public Health
	11:30 - 12:00 PM	Psychiatric Issues in HIV Patients With Liver Disease Andrew F. Angelino, MD, DFAPA Johns Hopkins University School of Medicine
	12:00 - 12:15 PM	SELECTED ORAL PRESENTATION Impact of Treating Depression in Hepatitis C/HIV Coinfected Patients: A Significant Benefit from Early Screening and Treatment Laveeza Bhatti, MD, PhD AIDS Healthcare Foundation
	12:15 - 1:00 PM	Clinical Case Lunch Breakout: Meet the Professor
	1:00 - 1:20 PM	Panel Discussion: Drug/Psychological Management Issues Andrew F. Angelino, MD, DFAPA Jeffrey H Samet, MD, MA, MPH
	1:20 - 1:50 PM	NIH Research Agenda Susan W. Brobst, PhD National Institute of Allergy and Infectious Diseases
	1:50 - 2:00 PM	Closing Remarks Kenneth E. Sherman, MD, PhD

We gratefully recognize the following independent educational grants in support of this activity: